Standard BioTools Reports Fourth Quarter and Full Year 2022

Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP...

Related Keywords

United States ,American ,Peter Denardo ,Michael Egholm ,Linkedin ,Twitter ,Standard Biotools Inc ,Nasdaq ,Exchange Commission ,American Association For Cancer Research ,Research Use ,Youtube ,Fluidigm Corporation ,Facebook ,Chief Executive Officer ,Standard Biotools ,Mass Cytometry ,With Proteomics ,Imaging Mass Cytometry ,Imaging System ,American Association ,Cancer Research ,Investor Relations ,Standard Biotools Investor Relations ,Supplemental Financial Information ,Regarding Use ,Private Securities Litigation Reform Act ,Standard Biotool ,Emergency Use Authorization ,Annual Report ,Seriesb Preferred ,Nasdaq Lab ,